Literature DB >> 35025664

Olfactory receptor 2 in vascular macrophages drives atherosclerosis by NLRP3-dependent IL-1 production.

Marco Orecchioni1, Kouji Kobiyama1,2, Holger Winkels1,3, Yanal Ghosheh1, Sara McArdle4, Zbigniew Mikulski4, William B Kiosses4, Zhichao Fan1,5, Lai Wen1, Yunmin Jung1, Payel Roy1, Amal J Ali1, Yukiko Miyamoto6, Matthew Mangan7, Jeffrey Makings1, Zhihao Wang1, Angela Denn4, Jenifer Vallejo1, Michaela Owens1, Christopher P Durant1, Simon Braumann3, Navid Mader8, Lin Li9, Hiroaki Matsunami10, Lars Eckmann6, Eicke Latz7, Zeneng Wang9, Stanley L Hazen9,11, Klaus Ley1,12.   

Abstract

Atherosclerosis is an inflammatory disease of the artery walls and involves immune cells such as macrophages. Olfactory receptors (OLFRs) are G protein–coupled chemoreceptors that have a central role in detecting odorants and the sense of smell. We found that mouse vascular macrophages express the olfactory receptor Olfr2 and all associated trafficking and signaling molecules. Olfr2 detects the compound octanal, which activates the NLR family pyrin domain containing 3 (NLRP3) inflammasome and induces interleukin-1β secretion in human and mouse macrophages. We found that human and mouse blood plasma contains octanal, a product of lipid peroxidation, at concentrations sufficient to activate Olfr2 and the human ortholog olfactory receptor 6A2 (OR6A2). Boosting octanal levels exacerbated atherosclerosis, whereas genetic targeting of Olfr2 in mice significantly reduced atherosclerotic plaques. Our findings suggest that inhibiting OR6A2 may provide a promising strategy to prevent and treat atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35025664     DOI: 10.1126/science.abg3067

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   63.714


  10 in total

1.  Olfactory receptors are not unique to the nose.

Authors:  Liam Drew
Journal:  Nature       Date:  2022-06       Impact factor: 49.962

Review 2.  Atherosclerosis: Recent developments.

Authors:  Johan L M Björkegren; Aldons J Lusis
Journal:  Cell       Date:  2022-05-02       Impact factor: 66.850

Review 3.  Targeting innate immunity-driven inflammation in CKD and cardiovascular disease.

Authors:  Thimoteus Speer; Stefanie Dimmeler; Stefan J Schunk; Danilo Fliser; Paul M Ridker
Journal:  Nat Rev Nephrol       Date:  2022-09-05       Impact factor: 42.439

Review 4.  New insights into macrophage subsets in atherosclerosis.

Authors:  Yurong Wang; Qiong Wang; Danyan Xu
Journal:  J Mol Med (Berl)       Date:  2022-08-05       Impact factor: 5.606

5.  A new age for (mucosal) NeuroImmunology.

Authors:  Gerard Eberl
Journal:  Mucosal Immunol       Date:  2022-10-18       Impact factor: 8.701

Review 6.  Immune Cell Plasticity in Inflammation: Insights into Description and Regulation of Immune Cell Phenotypes.

Authors:  Andreas Margraf; Mauro Perretti
Journal:  Cells       Date:  2022-06-02       Impact factor: 7.666

Review 7.  Macrophages in Atheromatous Plaque Developmental Stages.

Authors:  Alexander von Ehr; Christoph Bode; Ingo Hilgendorf
Journal:  Front Cardiovasc Med       Date:  2022-04-25

8.  Olfactory receptor 2 activation in macrophages: novel mediator of atherosclerosis progression.

Authors:  Zuowen He; Dao Wen Wang
Journal:  Signal Transduct Target Ther       Date:  2022-07-21

9.  A cuproptosis and copper metabolism-related gene prognostic index for head and neck squamous cell carcinoma.

Authors:  Shuaiyuan Zhang; Lujin Zhang; Huanzi Lu; Yihuan Yao; Xiaoyong Liu; Jingsong Hou
Journal:  Front Oncol       Date:  2022-08-22       Impact factor: 5.738

Review 10.  Vascular homeostasis in atherosclerosis: A holistic overview.

Authors:  Suowen Xu; Qing Rex Lyu; Iqra Ilyas; Xiao-Yu Tian; Jianping Weng
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.